在血管疾病中SERCA的作用,一个潜在的治疗点
1Department of Geriatric Cardiology, The First Hospital of China Medical University, China.
Cell calcium
|May 14, 2025
概括
/内细胞网膜Ca2+-ATPase (SERCA) 蛋白质对于细胞 (Ca2+) 平衡至关重要. 塞尔卡功能障碍与慢性疾病有关,突出了其对Ca2+不平衡障碍,特别是血管疾病的治疗潜力.
科学领域:
- 生物化学和分子生物学
- 心血管研究研究心血管研究
- 细胞生理学 细胞生理学
背景情况:
- /内分泌网膜Ca2+-ATPase (SERCA) 活跃地将离子 (Ca2+) 从细胞质运输到/内分泌网膜 (SR/ER).
- 塞尔卡在维持细胞Ca2+平衡中起着至关重要的作用,这对各种细胞功能至关重要.
- 在SERCA活动中的功能障碍越来越多地与破坏的Ca2+信号传递,内分泌网膜 (ER) 压力和慢性疾病的发病有关.
研究的目的:
- 审查SERCA功能与各种血管疾病的发展之间的复杂关系.
- 探索SERCA作为一种潜在的治疗点,用于管理以不平衡为特征的疾病.
主要方法:
- 文献综述综合了关于SERCA在细胞生理学中的作用的当前研究.
- 对与特定血管病理相关联的SERCA功能障碍研究的分析.
- 检查支持基于SERCA的治疗策略的证据.
主要成果:
- SERCA 功能障碍是细胞 Ca2+ 稳定性受损的重要因素.
- 由于SERCA问题而破坏的Ca2+平衡有助于ER压力.
- 证据强烈表明,SERCA活动与各种血管疾病的病理生理学之间存在联系.
结论:
- 塞尔卡是细胞Ca2+恒温的关键调节者,也是血管健康的关键参与者.
- 对SERCA的治疗调节为治疗与Ca2+失调相关的血管疾病提供了有希望的途径.
- 对SERCA在血管疾病中的机制进行进一步的研究是有必要的,以开发有效的治疗方法.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
329
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
329
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
1.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
1.9K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
01:20Overview of the Vascular System
2.7K
The vascular system comprises an extensive network of arteries, capillaries, and veins. The vascular system can be broadly divided into the blood and lymphatic systems. Typically, blood vessels can be categorized into three histological regions: tunica intima, tunica media, and tunica adventitia. The tunica intima consists of a single layer of endothelial cells attached to the basal lamina. Underlying the basal lamina is a connective tissue layer and an elastic lamina that gives stability and...
2.7K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
107
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
107